Startup profile · funding coverage
Arboretum LifeSciences funding, valuation and investors
Molecular-information company expanding genetic testing and precision medicine into common diseases.
Keep track of Arboretum LifeSciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$30M · October 6, 2026
Latest known valuation
Undisclosed
Series A · October 6, 2026
Total disclosed equity funding
$30M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Cambridge, Massachusetts, United States
Overview
Arboretum LifeSciences integrates genetic testing, clinical data and software to support care, patient identification and drug development in cardiovascular, metabolic and neurodegenerative disease.
Why Arboretum LifeSciences is interesting
It combines a clinical testing network with a longer-term strategy to acquire and spin out therapeutics matched to genetic profiles.
Product & use cases
The company partners with health systems to deliver genetic testing and with biopharma companies to identify genomically defined patient groups for research and clinical trials.
- Genetic testing for common diseases
- Genomically stratified trial recruitment
- Therapeutic asset identification and company creation
Key facts
- Launched with a $30M Series A.
- Targets cardiovascular, metabolic and neurodegenerative conditions beyond oncology and rare disease.
Funding history (newest first)
Series A
2026-10-06 $30M Valuation: Undisclosed- F-Prime Capital (lead)
- GV (lead)
- .406 Ventures (participant)
- Hims & Hers (participant)
- Amgen (participant)
Investors in our directory
Funds linked from Arboretum LifeSciences's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Leadership and operating experience connected to Broad Institute data science, combined with integrated testing and clinical-research workflows.
Competes with genetic-testing laboratories, precision-medicine data networks and technology-enabled clinical-recruitment platforms.
-
Invitae incumbent
Genetic testing and clinical interpretation.
-
Tempus AI adjacent
Clinical and molecular data platform for precision medicine.
-
Helix direct
Population genomics and health-system genetic testing.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Arboretum LifeSciences's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.